Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
Authors
Zweifel, MJayson, Gordon C
Reed, N S
Osborne, R
Hassan, B
Ledermann, J
Shreeves, G
Poupard, L
Lu, S-P
Balkissoon, J
Chaplin, D J
Rustin, G J S
Affiliation
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.Issue Date
2011-09
Metadata
Show full item recordAbstract
A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.Citation
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. 2011, 22 (9):2036-41 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdq708PubMed ID
21273348Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdq708